Case Report: Successful Treatment With Monoclonal Antibodies in One APDS Patient With Prolonged SARS-CoV-2 Infection Not Responsive to Previous Lines of Treatment

We described the case of a patient affected by activated PI3K-kinase delta syndrome (APDS) and a long-lasting and pauci-symptomatic SARS-CoV-2 infection, treated with multiple therapeutic agents including remdesivir and SARS-CoV-2-neutralizing monoclonal antibodies. We detected the clearance of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivalta, Beatrice, Amodio, Donato, Giancotta, Carmela, Santilli, Veronica, Pacillo, Lucia, Zangari, Paola, Cotugno, Nicola, Manno, Emma Concetta, Finocchi, Andrea, Bernardi, Stefania, Colagrossi, Luna, Gentile, Leonarda, Russo, Cristina, Perno, Carlo Federico, Rossi, Paolo, Cancrini, Caterina, Palma, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253383/
https://www.ncbi.nlm.nih.gov/pubmed/35799775
http://dx.doi.org/10.3389/fimmu.2022.891274
Descripción
Sumario:We described the case of a patient affected by activated PI3K-kinase delta syndrome (APDS) and a long-lasting and pauci-symptomatic SARS-CoV-2 infection, treated with multiple therapeutic agents including remdesivir and SARS-CoV-2-neutralizing monoclonal antibodies. We detected the clearance of the virus 105 days from the first positive swab and 7 days after monoclonal antibody administration. At genotyping, the SARS-CoV-2 virus resulted as wild type on all samples tested. This case shows the monoclonal antibodies’ good tolerability and efficacy in reducing viral shedding in long-lasting infections refractory to other treatments.

Ejemplares similares